Kevin Judice

Director

Kevin Judice is a biotechnology executive, serial entrepreneur, and lifelong surfer. He was most recently the co-founder and CEO of DICE therapeutics, which was acquired by Eli Lilly for $2.4 billion in 2023. Prior to that, he was a co-founder at Achaogen, Cidara, and Eidos, and held senior leadership roles at Theravance and Genentech. Kevin earned his Ph.D. in Organic Chemistry from UCLA and completed postdoctoral research at the University of California, Berkeley. He is a Henry Crown Fellow of the Aspen Institute and currently involved with various nonprofit and advisory organizations.